NKGen Biotech, Inc. presented additional Phase 1 clinical trial data on the use of its investigational autologous NK cell therapy, SNK01, to treat patients with Alzheimer?s disease (?AD?) at the Tau2024 Global Conference in Washington, D.C. The presentation contained data from an abstract entitled, ?Beneficial Effect on CSF and Plasma Tau Proteins and Cognitive Function in Alzheimer?s Disease Subjects Treated with Expanded Non-Genetically Modified Autologous Natural Killer Cells (SNK01).? In this Phase 1 study, SNK01 was administered intravenously (?IV?) every three weeks for a total of four treatments using a 3+3 dose escalation design (1, 2, and 4 x 109 cells) in patients with either mild, moderate, or severe AD (Median MMSE of 14). Cognitive assessments and CSF/plasma pTau217 and pTau181 analyses were performed at baseline and at 1 and 12 weeks after the final dose.

The primary endpoint was safety and secondary endpoints included changes in cognitive assessments and biomarker levels. Highlights from the Presentation: Of the 11 patients enrolled, 10 were evaluable ? median MMSE was 14.

SNK01 given via a simple IV appears to cross the blood brain barrier to improve Aß42/40, Tau, and alpha-synuclein protein levels in CSF. Despite 70% of patients treated at relatively low doses of SNK01, at one-week post-treatment (week 11): 50?70% of all enrolled patients in the trial had either stable or improved CDR-SB, ADAS-Cog and/or MMSE scores including one patient whose MMSE score improved from 14 to 23. 90% had either stable or improved ADCOMS scores.

50% of patients had a decrease in CSF pTau217. 80% had stable/decreased CSF pTau181 compared to baseline values. 30% had a decrease in plasma pTau217.

40% had a decrease in plasma pTau181. Where data were available, this decrease continued through week 22 (12 weeks after the last dose) for CSF pTau217 for all patients (n=4), for CSF pTau181 for 5/7 patients, for plasma pTau217 for 2/3 patients, and for plasma pTau181 for 3/4 patients. At week 11, the percent of patients with a stable/improved ADCOMS score who also had a decrease in CSF pTau was 56% for pTau217 and 78% for pTau181.

No treatment related adverse events were observed. SNK01 appears safe and well tolerated and the data suggest SNK01 may have potential clinical activity in AD while also reducing CSF and plasma Tau protein levels. A larger trial with a higher dosing/duration was initiated in the U.S. in 2023.